CERS - シ―ラス (Cerus Corporation) シ―ラス

 CERSのチャート


 CERSの企業情報

symbol CERS
会社名 Cerus Corp. (シ―ラス)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 シーラス(Cerus Corporation)は生物医学製品会社であり、血液の安全性を高めるために自社の「インターセプト・ブラッド・システム(INTERCEPT Blood System)」の商業化を中心に事業を展開する。同社は、血液安全セグメントを通じて事業を行う。同社のINTERCEPT血液システムは、生物学的複製を制御する技術に基づいて、輸血を目的とする寄贈血液成分中の血液媒介病原体を減少させるように設計される。同社のINTERCEPT血液システムは、ヒト免疫不全ウイルス(HIV)、西ナイル病、重症急性呼吸器症候群(SARS)、B型肝炎・C型肝炎、細菌や寄生虫を含むウイルスなどの血液媒介病原体を標的とし、それらを不活性化するように設計される 血小板、血漿及び赤血球輸血製品の治療特性を保持しながら、有害な白血球として使用できる。同社のINTERCEPT血液システムは、血漿、血小板及び赤血球などの血液成分とともに使用される。   シ―ラスは米国の生物医学的製品企業。血液の安全性を高めるためのシステム「インタ―セプト・ブラッド・システム」を開発。献血血液成分中にある血液媒介病原体を不活性化させる。同システムは欧州、独立国家共同体、中東、その他の国々の血液銀行、病院、大学や政府機関に直接販売される。本社はカリフォルニア州。   Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.
本社所在地 2550 Stanwell Dr. Concord CA 94520 USA
代表者氏名 Daniel N. Swisher ダニエル・N・スウィッシャー
代表者役職名 Independent Chairman of the Board
電話番号 +1 925-288-6000
設立年月日 33482
市場名 NASDAQ National Market System
ipoyear 1997年
従業員数 215人
url www.cerus.com
nasdaq_url https://www.nasdaq.com/symbol/cers
adr_tso
EBITDA EBITDA(百万ドル) -47.46400
終値(lastsale) 6.3
時価総額(marketcap) 843027544.8
時価総額 時価総額(百万ドル) 887.18620
売上高 売上高(百万ドル) 68.18600
企業価値(EV) 企業価値(EV)(百万ドル) 805.11020
当期純利益 当期純利益(百万ドル) -52.07100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Cerus Corporation revenues increased 86% to $36.5M. Net loss decreased 24% to $27.2M. Revenues reflect Revenue increase of 75% to $29M Government contracts revenue increase from $3.1M to $7.5M. Lower net loss reflects Foreign exchange loss decrease of 49% to $30K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.34 to -$0.21.

 CERSのテクニカル分析


 CERSのニュース

   Cerus (CERS) Q1 2022 Earnings Call Transcript  2022/05/06 06:30:33 The Motley Fool
CERS earnings call for the period ending March 31, 2022.
   Cerus Corporation (CERS) CEO Obi Greenman on Q1 2022 Results - Earnings Call Transcript  2022/05/06 02:15:03 Seeking Alpha
Cerus Corporation (NASDAQ:NASDAQ:CERS) Q1 2022 Earnings Conference Call May 05, 2022 4:30 PM ET Company Participants Matt Notarianni – Senior Director-Investor Relations Obi Greenman –…
   Cerus GAAP EPS of -$0.07 beats by $0.01, revenue of $43.02M beats by $5.53M  2022/05/05 20:08:25 Seeking Alpha
Cerus press release (CERS): Q1 GAAP EPS of -$0.07 beats by $0.01.Revenue of $43.02M (+45.5% Y/Y) beats by $5.53M.Increasing Full-Year 2022 Product Revenue Guidance Range from…
   Cerus Corporation Announces First Quarter 2022 Financial Results and Increases Full Year 2022 Product Revenue Guidance Range  2022/05/05 20:00:00 Wallstreet:Online
Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2022. Recent developments and highlights include: First quarter 2022 total revenue of $43.0 million, reflecting a 46% increase over the prior year period. Total revenue was composed of (in thousands, except %): Three
   Cerus Corporation (NASDAQ: CERS) Stock: Now At 11.87% Gain Since Low, This Stock Just Hasn’t Warmed Up  2022/05/04 14:30:00 Stocks Register
Cerus Corporation (NASDAQ:CERS) price closed higher on Tuesday, May 03, jumping 1.87% above its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << A look at the daily price movement shows that the last close reads $4.81, with intraday deals fluctuated between $4.78 and $5.00. The … Cerus Corporation (NASDAQ: CERS) Stock: Now At 11.87% Gain Since Low, This Stock Just Hasn’t Warmed Up Read More »
   Cerus Corporation to Participate at the Cowen 42nd Annual Health Care Conference  2022/02/25 13:00:00 Business Wire
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that Kevin D. Green, Cerus’ chief financial officer, is scheduled to participate at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 1:30 p.m. EST. A live webcast of the event will be available on the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for approximately two weeks following the completion of the event. ABOUT CERUS Cerus Co
   Cerus Reports Narrower Quarterly Loss As INTERCEPT Platelet Kits Lift Q4 Sales  2022/02/23 12:26:13 Benzinga
Cerus Corp''s (NASDAQ: CERS ) Q4 FY21 product revenue was $39.9 million , compared to $28.2 million, driven by increased sales of INTERCEPT platelet kits to blood center customers across the U.S. Total revenue increased 49% to $50.1 million, beating the consensus of $44.2 million. Product gross profit was $20.4 million and, for the second consecutive quarter, was the highest in the company''s history, Full story available on Benzinga.com
   Cerus (CERS) Q4 2021 Earnings Call Transcript  2022/02/23 03:00:34 The Motley Fool
CERS earnings call for the period ending December 31, 2021.
   Cerus Corporation (CERS) CEO Obi Greenman on Q4 2021 Results - Earnings Call Transcript  2022/02/23 01:00:06 Seeking Alpha
   Cerus GAAP EPS of -$0.05 beats by $0.03, revenue of $39.87M in-line  2022/02/22 21:08:29 Seeking Alpha
Cerus press release (CERS): Q4 GAAP EPS of -$0.05 beats by $0.03.Revenue of $39.87M (+41.4% Y/Y) in-line.The Company is reiterating its 2022 annual product revenue guidance range of
   Cerus Corporation (CERS) Q3 2021 Earnings Call Transcript  2021/11/03 09:01:09 The Motley Fool
CERS earnings call for the period ending September 30, 2021.
   Cerus Corporation (CERS) CEO Obi Greenman on Q3 2021 Results - Earnings Call Transcript  2021/11/03 02:09:06 Seeking Alpha
   Silvercrest Asset Management Group LLC Has $6.40 Million Stock Holdings in Cerus Co. (NASDAQ:CERS)  2021/10/24 11:36:45 Transcript Daily
Silvercrest Asset Management Group LLC lessened its holdings in Cerus Co. (NASDAQ:CERS) by 0.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,083,559 shares of the biotechnology companys stock after selling 3,679 shares during the period. Silvercrest Asset Management Group LLC []
   Premier Asset Management LLC Sells 50,231 Shares of Cerus Co. (NASDAQ:CERS)  2021/10/23 15:22:44 Dakota Financial News
Premier Asset Management LLC lowered its position in Cerus Co. (NASDAQ:CERS) by 16.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 250,213 shares of the biotechnology companys stock after selling 50,231 shares during the quarter. Premier Asset Management LLCs holdings in Cerus were []
   Zika Vaccines Market Is Booming Worldwide With Top Manufacturers Cerus Corporation, Biken, GlaxoSmithKline  2021/10/19 08:59:13 OpenPR
The Zika vaccines market is expected to witness significant growth, due to high incidence of Zika virus infection. In November 2019, The European Centers for Disease Control confirmed the first three cases of Zika that started in southern France. Zika

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 シ―ラス CERS Cerus Corporation)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)